Recurrent focal segmental glomerulosclerosis (FSGS) is a major cause of kidney allograft failure and is often resistant to available treatments. Recent reports support anti-CD38 therapy with daratumumab, but the evidence remains limited to small studies.
This article has not been confirmed as an AI-rewritten patient summary. Please review the original publication for context.
Original publication: www.kireports.org
Medical information notice: This article is for general education only. It is not personal medical advice. Discuss treatment decisions with your healthcare team.